80 related articles for article (PubMed ID: 1924475)
1. Tumor collagenase stimulating factor (TCSF) and tumor autocrine motility factor (TAMF) in bladder cancer.
Javadpour N; Guirguis R
Prog Clin Biol Res; 1991; 370():393-8. PubMed ID: 1924475
[No Abstract] [Full Text] [Related]
2. Tumor collagenase-stimulating factor and tumor autocrine motility factor as tumor markers in bladder cancer--an update.
Javadpour N; Guirguis R
Eur Urol; 1992; 21 Suppl 1():1-4. PubMed ID: 1425830
[TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of a tumor-cell-derived collagenase-stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers.
Muraoka K; Nabeshima K; Murayama T; Biswas C; Koono M
Int J Cancer; 1993 Aug; 55(1):19-26. PubMed ID: 8344748
[TBL] [Abstract][Full Text] [Related]
4. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
[TBL] [Abstract][Full Text] [Related]
5. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
[TBL] [Abstract][Full Text] [Related]
6. Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase.
Kataoka H; DeCastro R; Zucker S; Biswas C
Cancer Res; 1993 Jul; 53(13):3154-8. PubMed ID: 8319225
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic markers in transitional carcinoma of the bladder].
Blasco E; Gutiérrez-Hoyos A; Garrido C; Arozena F
Arch Esp Urol; 1991; 44(1):47-52. PubMed ID: 2064423
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
Guo CC; Fine SW; Epstein JI
Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
[TBL] [Abstract][Full Text] [Related]
9. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
10. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
Bian W; Xu Z
Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
el-Ahmady O; Halim AB; el-Din AG
Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
[TBL] [Abstract][Full Text] [Related]
12. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.
Sánchez-Carbayo M; Herrero E; Megias J; Mira A; Espasa A; Chinchilla V; Soria F
J Urol; 1999 Apr; 161(4):1110-5. PubMed ID: 10081849
[TBL] [Abstract][Full Text] [Related]
13. Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma.
Rosenthal EL; Shreenivas S; Peters GE; Grizzle WE; Desmond R; Gladson CL
Laryngoscope; 2003 Aug; 113(8):1406-10. PubMed ID: 12897567
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
15. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
16. Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor.
Tachibana M; Miyakawa A; Tazaki H; Nakamura K; Kubo A; Hata J; Nishi T; Amano Y
Cancer Res; 1995 Aug; 55(15):3438-43. PubMed ID: 7542171
[TBL] [Abstract][Full Text] [Related]
17. Telomerase activity in patients with transitional cell carcinoma: a preliminary study.
Rahat MA; Lahat N; Gazawi H; Resnick MB; Sova Y; Ben-Ari G; Cohen M; Stein A
Cancer; 1999 Feb; 85(4):919-24. PubMed ID: 10091771
[TBL] [Abstract][Full Text] [Related]
18. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
[TBL] [Abstract][Full Text] [Related]
19. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
20. [Pathologic anatomy of superficial tumors of the bladder].
Billerey C; Sibony M; Gattegno B; Chopin D
Prog Urol; 2001 Nov; 11(5):805-63. PubMed ID: 11769082
[No Abstract] [Full Text] [Related]
[Next] [New Search]
